Treatment of dyslipidemia in kidney transplantation

References

• Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019;34:760–773.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Cohen JJ, Harrington JT, et al. Ischemic heart disease after renal transplantation. Kidney Int. 2002;61:356–369.
   PubMed Web of Science ®Google Scholar
• Hart A, Weir MR, Kasiske BL. Cardiovascular risk assessment in kidney transplantation. Kidney Int. 2015;87:527–534.
   Web of Science ®Google Scholar
• Awan AA, Niu J, Pan JS, et al. Trends in the causes of death among kidney transplant recipients in the United States (1996–2014). Am J Nephrol. 2018;48:472–481.
   PubMed Web of Science ®Google Scholar
• Devine PA, Courtney AE, Maxwell AP. Cardiovascular risk in renal transplant recipients. J Nephrol. 2019;32:389–399.
   PubMed Web of Science ®Google Scholar
• Fellström B, Holdaas H, Jardine A. Cardiovascular disease in renal transplantation: management by statins. Transplant Rev. 2004;18:122–128.
   Google Scholar
• Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82:603–611.
   PubMed Web of Science ®Google Scholar
• Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther. 2003;17:265–285.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140:e596–e646.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Graziani G. Education and counseling of renal transplant recipients. J Nephrol. 2012;25:879–889.
   PubMed Web of Science ®Google Scholar
• Mitsui Y, Sadahira T, Araki M, et al. Clinical impact of abdominal fat distribution measured by 3-D computed tomography volumetry on post-transplant renal function in recipients after living kidney transplantation: a retrospective study. Clin Exp Nephrol. 2019;23:415–424.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang J, Ye J, et al. Separate and combined associations of physical activity and obesity with lipid-related indices in non-diabetic and diabetic patients. Lipids Health Dis. 2019;18(1):49.
   PubMedGoogle Scholar
• Takahashi A, Hu SL, Bostom A. Physical activity in kidney transplant recipients: a review. Am J Kidney Dis. 2018;72:433–443.
   PubMed Web of Science ®Google Scholar
• Paoletti E, Citterio F, Corsini A, et al. Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. J Nephrol. 2019;33:69–82.
   PubMed Web of Science ®Google Scholar
• Chen G, Gao L, Li X. Effects of exercise training on cardiovascular risk factors in kidney transplant recipients: a systematic review and meta-analysis. Ren Fail. 2019;41:408–418.
   PubMed Web of Science ®Google Scholar
• Costa de Oliveira CM, Mota MU, Mota RS, et al. Prevalence and staging of chronic kidney disease in renal transplant recipients. Clin Transplant. 2009;23:628–636.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol. 2016;12:37–47.
   PubMed Web of Science ®Google Scholar
• Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;139:e1144–e1161.
   Google Scholar
• Morita SY. Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis. Biol Pharm Bull. 2016;39:1–24.
   PubMed Web of Science ®Google Scholar
• Israni AK, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study. Am J Transplant. 2010;10:338–353.
   PubMed Web of Science ®Google Scholar
• Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012;12:1975–1982.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Prasad GVR. Post-transplant dyslipidemia: mechanisms, diagnosis and management. World J Transplant. 2016;6:125–134.
   PubMedGoogle Scholar
• Jackson SP, Calkin AC. The clot thickens – oxidized lipids and thrombosis. Nat Med. 2007;13:1015–1016.
   PubMed Web of Science ®Google Scholar
• Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086–1095.
   PubMed Web of Science ®Google Scholar
• Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010;19:393–402.
   PubMed Web of Science ®Google Scholar
• Izquierdo-Lahuerta A, Martínez-García C, Medina-Gómez G. Lipotoxicity as a trigger factor of renal disease. J Nephrol. 2016;29:603–610.
   PubMed Web of Science ®Google Scholar
• Wahl P, Ducasa GM, Fornoni A. Systemic and renal lipids in kidney disease development and progression. Am J Physiol - Ren Physiol. 2016;310:F433–F445.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B–25B.
   PubMed Web of Science ®Google Scholar
• Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.
   PubMed Web of Science ®Google Scholar
• Kroner PT, Mareth K, Raimondo M, et al. Acute pancreatitis in advanced chronic kidney disease and kidney transplant recipients: results of a us nationwide analysis. Mayo Clin Proc Innov Qual Outcomes. 2019;3:160–168.
   PubMedGoogle Scholar
• Garg R, Rustagi T. Management of hypertriglyceridemia induced acute pancreatitis. Biomed Res Int. 2018;4721357. DOI:https://doi.org/10.1155/2018/4721357
   Google Scholar
• Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21:37–46.
   PubMed Web of Science ®Google Scholar
• Zanotti I, Greco D, Lusardi G, et al. Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion. PLoS One. 2013;8:71572.
   PubMed Web of Science ®Google Scholar
• Tavori H, Rashid S, Fazio S. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis. 2015;238:264–270.
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63:331–338.
   PubMed Web of Science ®Google Scholar
• Badiou S, Garrigue V, Dupuy AM, et al. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? Transplant Proc. 2006;38:2314–2316.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775–782.
   PubMed Web of Science ®Google Scholar
• Tory R, Sachs-Barrable K, Goshko CB, et al. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. Transplantation. 2009;88:62–68.
   PubMed Web of Science ®Google Scholar
• Kurdi A, Martinet W, de Meyer GRY. mTOR inhibition & cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation. 2017;102(Suppl):S44–S46.
   Google Scholar
• Andrés V, Castro C, Campistol JM. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant. 2006;21(Suppl 3):iii14–17.
   PubMedGoogle Scholar
• Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43:1170–1180.
   PubMed Web of Science ®Google Scholar
• Ponticelli C. The pros and the cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol. 2014;10:295–305.
   PubMed Web of Science ®Google Scholar
• Kurdi A, De Meyer GRY, Martinet W. Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharmacol. 2016;102(2S Suppl 1):S44–S46.
   Google Scholar
• Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. Cochrane Database Syst Rev. 2017;7:CD006750.
   PubMedGoogle Scholar
• Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14:1055–1070.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499–505.
   PubMed Web of Science ®Google Scholar
• Fuhrmann A, Lopes P, Sereno J, et al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem Pharmacol. 2014;88:216–228.
   PubMed Web of Science ®Google Scholar
• Hemmer MC, Wierer M, Schachtrup K, et al. E47 modulates hepatic glucocorticoid action. Nat Commun. 2019;10(1):306.
   PubMed Web of Science ®Google Scholar
• Toth P. Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr Vasc Pharmacol. 2014;12:653–657.
   PubMed Web of Science ®Google Scholar
• Pascual J, Galeano C, Royuela A, et al. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation. 2010;90:343–349.
   PubMed Web of Science ®Google Scholar
• Pascual J, van Hoff JP, Salmela K, et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation. 2006;82:55–61.
   PubMed Web of Science ®Google Scholar
• Bril F, Castro V, G. Centurion I, et al. A systematic approach to assess the burden of drug interactions in adult kidney transplant patients. Curr Drug Saf. 2016;11:156–163.
   PubMed Web of Science ®Google Scholar
• Vanhove T, Remijsen Q, Kuypers D, et al. Drug–drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplant Rev. 2017;31:69–77.
   Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111–188. .
   Web of Science ®Google Scholar
• Moore RA, Callahan MF, Cody M, et al. The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation. Transplantation. 1990;49:60–62.
   PubMed Web of Science ®Google Scholar
• Fong JVN, Moore LW. Nutrition trends in kidney transplant recipients: the importance of dietary monitoring and need for evidence-based recommendations. Front Med. 2018;5:302.
   Web of Science ®Google Scholar
• Malhotra A, Shafiq N, Arora A, et al. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev. 2014;6:CD 001918. DOI:https://doi.org/10.1002/14651858.CD001918.pub3
   Google Scholar
• Hamasaki H, Noda M, Moriyama S, et al. Daily physical activity assessed by a triaxial accelerometer is beneficially associated with waist circumference, serum triglycerides, and insulin resistance in Japanese patients with prediabetes or untreated early type 2 diabetes. J Diabetes Res. 2015;2015:526201.
   PubMedGoogle Scholar
• Hu B, Liu XY, Zheng Y, et al. High physical activity is associated with an improved lipid profile and resting heart rate among healthy middle-aged chinese people. Biomed Environ Sci. 2015;28:263–271.
   PubMed Web of Science ®Google Scholar
• Calella P, Hernández-Sánchez S, Garofalo C, et al. Exercise training in kidney transplant recipients: a systematic review. J Nephrol. 2019;32:567–579.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Steiner G, Wilson DR, et al. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med. 1979;91:554–559.
   PubMed Web of Science ®Google Scholar
• Montagnino G, Tarantino A, Segoloni GP, et al. Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation. J Am Soc Nephrol. 2001;12:2163–2169.
   PubMed Web of Science ®Google Scholar
• Krämer BK, Klinger M, Vítko Š, et al. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Transplantation. 2012;94:492–498.
   PubMed Web of Science ®Google Scholar
• Hohage H, Welling U, Heck M, et al. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors. Int Immunopharmacol. 2005;5:117–123.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Sánchez-Fructuoso A, Franco A, et al. Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. Transpl Int. 2012;25:391–400.
   PubMed Web of Science ®Google Scholar
• Darres A, Ulloa C, Brakemeier S, et al. Conversion to belatacept in maintenance kidney transplant patients: a retrospective multicenter European study. Transplantation. 2018;102(9):1545–1552.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase ii study. Clin J Am Soc Nephrol. 2011;6:430–439.
   PubMed Web of Science ®Google Scholar
• Diekmann F. Immuosuppressive minimization with mTOR inhibitors and Belatacept. Transpl Int. 2015;28:921–927.
   PubMed Web of Science ®Google Scholar
• Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol. 2010;21:298–304.
   PubMed Web of Science ®Google Scholar
• Ferri N, Arnaboldi L, Orlandi A, et al. Effect of S(-) perillic acid on protein prenylation and arterial smooth muscle cell proliferation. Biochem Pharmacol. 2001;62:1637–1645.
   PubMed Web of Science ®Google Scholar
• Shahbaz SK, Sadeghi M, Koushki K, et al. Regulatory T cells: possible mediators for the anti-inflammatory action of statins. Pharmacol Res. 2019;149:104469.
   PubMed Web of Science ®Google Scholar
• Mora S, Ridker PM. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER) – can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2):33A–41A.
   PubMed Web of Science ®Google Scholar
• Watson KE. The JUPITER trial: how will it change clinical practice? Rev Cardiovasc Med. 2009;10:91–96.
   PubMed Web of Science ®Google Scholar
• Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229–243.
   PubMed Web of Science ®Google Scholar
• Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis. 2005;45:2–14.
   PubMed Web of Science ®Google Scholar
• Idzerda NMA, Pena MJ, Parving HH, et al. Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrol Dial Transplant. 2019;34:1699–1706.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012.1022.
   Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C–60C.
   PubMed Web of Science ®Google Scholar
• Ward NC, Watts GF, Eckel RH. Statin toxicity: mechanistic insights and clinical implications. Circ Res. 2019;124:328–350.
   PubMed Web of Science ®Google Scholar
• Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–1309.
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellström B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929–2936.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014;(1):CD 005019. DOI:https://doi.org/10.1002/14651858.CD005019.pub4
   Google Scholar
• Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:971–972.
   PubMed Web of Science ®Google Scholar
• Su X, Zhang L, Lv J, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67:881–892.
   PubMed Web of Science ®Google Scholar
• Geng Q, Ren J, Song J, et al. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014;114:562–570.
   PubMed Web of Science ®Google Scholar
• Co MLF, Agdamag AC, Co MZ, et al. Intensity-dependent benefit of statins in survival among prospective kidney transplant patients. Am J Cardiol. 2019;123:254–259.
   PubMed Web of Science ®Google Scholar
• Han N, Han SH, Song YK, et al. Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation. Ther Clin Risk Manag. 2017;13:1513–1520.
   PubMed Web of Science ®Google Scholar
• Morival C, Westerlynck R, Bouzillé G, et al. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol. 2018;74:525–534.
   PubMed Web of Science ®Google Scholar
• Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins Achilles heel? Curr Med Res Opin. 2011;27:1551–1562.
   PubMed Web of Science ®Google Scholar
• Nazir S, Lohani S, Tachamo N, et al. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol. 2017;23:149–154.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lach B, Provias JP, et al. Statin-associated autoimmune myopathies: a pathophysiologic spectrum. Can J Neurol Sci. 2014;41:638–647b.
   PubMed Web of Science ®Google Scholar
• Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms? Curr Opin Lipidol. 2015;26:228–235.
   PubMed Web of Science ®Google Scholar
• Van Hooff JP, Christiaans MHL, Van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation. 2005;69:1465–1469.
   Google Scholar
• Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2017;37:173–178.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17:25–37.
   PubMed Web of Science ®Google Scholar
• Ward FL, John R, Bargman JM, et al. Renal tubular toxicity associated with rosuvastatin therapy. Am J Kidney Dis. 2017;69:473–476.
   PubMed Web of Science ®Google Scholar
• Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–428.
   PubMed Web of Science ®Google Scholar
• Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther. 1999;24:397–408. .
   PubMed Web of Science ®Google Scholar
• Li PKT, Mak TWL, Wang AYM, et al. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther. 1995;33:246–248.
   PubMed Web of Science ®Google Scholar
• Wanitchanont A, Somparn P, Vadcharavivad S, et al. Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. Transplant Proc. 2014;46:418–421.
   PubMed Web of Science ®Google Scholar
• Åsberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs. 2003;63:367–378.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;73:e285–e350. .
   Google Scholar
• Kohnle M, Pietruck F, Kribben A, et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant. 2006;6:205–208.
   PubMed Web of Science ®Google Scholar
• Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation. 2006;6:205–208.
   Google Scholar
• Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60:2061–2071.
   PubMed Web of Science ®Google Scholar
• Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15:1993–1999.
   PubMed Web of Science ®Google Scholar
• Amend KL, Landon J, Thyagarajan V, et al. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured us population. Ann Pharmacother. 2011;45:1230–1239.
   PubMed Web of Science ®Google Scholar
• Polanco N, Hernández E, González E, et al. Fibrate-induced deterioration of renal function. Nefrologia. 2009;29:208–213.
   PubMed Web of Science ®Google Scholar
• Angeles C, Lane BP, Miller F, et al. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am J Kidney Dis. 2004;44:543–550.
   PubMed Web of Science ®Google Scholar
• Alvarez PA, Egozcue J, Sleiman J, et al. Severe neutropenia in a renal transplant patient suggesting an interaction between mycophenolate and fenofibrate. Curr Drug Saf. 2012;7:24–29.
   PubMedGoogle Scholar
• Lim AKH, Manley KJ, Roberts MA, et al. Fish oil for kidney transplant recipients. Cochrane Database Syst Rev. 2016;8:CD008252. DOI:https://doi.org/10.1002/14651858.CD005282.pub3
   Google Scholar
• Eisenga MF, Zelle DM, Sloan JH, et al. High serum PCSK9 is associated with increased risk of new-onset diabetes after transplantation in renal transplant recipients. Diabetes Care. 2017;40:894–901.
   PubMed Web of Science ®Google Scholar
• Kühl M, Binner C, Jozwiak J, et al. Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. PLoS One. 2019;14:e0210373.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;36:1713–1722.
   Google Scholar
• Vallejo-Vaz AJ, Ray KK, Ginsberg HN, et al. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019;288:85–93.
   PubMed Web of Science ®Google Scholar
• Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93:1397–1408.
   PubMed Web of Science ®Google Scholar
• Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and safety of evolocumab in chronic kidney disease in the fourier trial. J Am Coll Cardiol. 2019;73:2961–2970.
   PubMed Web of Science ®Google Scholar
• Moayedi Y, Kozuszko S, Knowles JW, et al. Safety and efficacy of PCSK9 inhibitors after heart transplantation. Can J Cardiol. 2019;35(1):104e1–104e3.
   Web of Science ®Google Scholar
• Ordóñez-Fernández L, Rodríguez-Ferreras A, Carriles C, et al. Pneumonia in a patient with kidney transplant treated with alirocumab and everolimus. Farm Hosp. 2019;43:74–76.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41–51.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Digenio A, Alexander VJ, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). J Clin Lipidol. 2017;12:920–927.
   Google Scholar
• Rocha NA, East C, Zhang J, et al. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep. 2017;19(12):62.
   PubMed Web of Science ®Google Scholar
• Sudharshan S, Javaheri A. Cholesterol efflux in the transplant patient. Curr Opin Endocrinol Diabetes Obes. 2018;25:143–146.
   PubMedGoogle Scholar
• Heudobler D, Rechenmacher M, Lüke F, et al. Peroxisome proliferator-activated receptors (PPAR)γ agonists as master modulators of tumor tissue. Int J Mol Sci. 2018;19(11):pii E3540.
   Web of Science ®Google Scholar
• Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16. DOI:https://doi.org/10.1186/s12933-017-0602-y.
   Google Scholar
• Fruchart JC, Santos RD. SPPARM alpha: the Lazarus effect. Curr Opin Lipidol. 2019;16(1):124.
   Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. J Am Med Assoc. 2019;322:1780–1788.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2019;2047487319864671. (ahead of print). DOI:https://doi.org/10.1177/2047487319864671
   Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–1032.
   PubMed Web of Science ®Google Scholar